GAO calls for better FDA oversight of IRBs
Regulatory NewsJoanne S. Eglovitch
Clinical TrialsComplianceEthicsNorth AmericaPharmaceuticalsResearch, Design and DevelopmentRegulatory NewsJoanne S. EglovitchClinical TrialsComplianceEthicsNorth AmericaPharmaceuticalsResearch, Design and Development